Last updated 2026-09-04
- Went public on TASE (EVGN), Jun 2007
- Raised $28M Follow-on PO, Jan 2021
- Raised $73.8M Follow-on PO, Nov 2013
Total raised
$153.2M
Stage
Public
Founded
2002
Headcount
38
HQ
Rehovot, Israel
Sector
Health Tech & Life Sciences
About
Evogene is a computational biology and chemistry company that applies big data and artificial intelligence to the discovery and development of life-science based products. The company's core technology is its ChemPass AI™ platform, a proprietary generative AI tech-engine that creates highly potent, unique small molecules optimized across multiple critical parameters, increasing the probability of success while reducing time and costs. Evogene operates through subsidiaries focused on human microbiome-based therapeutics (Biomica Ltd), medical cannabis (Canonic Ltd), agricultural biologicals (Lavie Bio Ltd), agriculture chemicals (AgPlenus Ltd), and castor oil production solutions (Casterra Ltd). Evogene has repositioned itself around ChemPass AI as its core engine, serving two main verticals: Pharma (discovery of novel small-molecule therapeutics) and Agriculture (crop protection innovation and related ag-tech applications).
Funding history · 12 rounds · $153.2M total
14 events/rounds · $153.2M Total Funding: $900K in Private Equity, $237.1M in Public Equity
Jul 2026
Follow-on PO
$3.3M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Mar 2024
Follow-on PO
$7.3M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Jul 2023
Follow-on PO
$8.5M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Mar 2022
Follow-on PO
$19.4M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Jan 2021
Follow-on PO
$28.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Nov 2020
Follow-on PO
$12.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Nov 2013
Follow-on PO
$73.8M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Jun 2009
B Round
Undisclosed
wikipedia.org
★ Syngenta
Sep 2008
A Round
Undisclosed
wikipedia.org
★ Ormat Group★ Leviev Group
Mar 2008
Follow-on PO
Undisclosed
tracxn.com
★ AquAgro Fund
Jun 2007
Grant
Undisclosed
wikipedia.org
★ Israel-Germany BioDisc program★ Israeli Ministry of Science and Technology★ Germany's Federal Ministry of Education and Research
Jan 2002
Headcount over time
38 employees (2026-09) · 1 point
Offices
Rehovot, Israel · HQ / main office
Q&A
- What was Evogene's most recent public offering?
- Evogene's most recent public offering was in July 2026, raising $3,288,113.
- What is Evogene's core technology?
- Evogene's core technology is its Computational Predictive Biology (CPB) platform, which integrates deep biological understanding with big data and AI to computationally discover and guide the development of life sciences products based on microbes, small molecules, and genetic elements.
- What is the status of Evogene's collaboration with Google Cloud for generative AI in small molecule design?
- In October 2024, Evogene announced a collaboration with Google Cloud to pioneer a generative AI foundation model for novel small molecule design. A major milestone in this collaboration, advancing ChemPass AI™ toward autonomous small molecule discovery and optimization, was announced in June 2026.
- What is the latest development regarding Evogene's subsidiary Lavie Bio's bio-fungicide program?
- In November 2024, Lavie Bio advanced its bio-fungicide LAV321, targeting Downy Mildew, to the pre-commercial stage following successful 2024 field trial results.
- What is the current employee count for Evogene?
- Evogene currently has 51–200 employees.
- What is the latest news on Evogene's subsidiary Casterra's operations in Africa?
- In October 2024, Casterra announced a key milestone in its operational expansion plan in Africa, with the completion of the first shipment of castor seeds grown and processed in Kenya.
- What is the status of Biomica's Phase I trial for its microbiome-based immuno-oncology drug?
- In January 2024, Biomica successfully completed Phase I trial enrollment for its microbiome-based immuno-oncology drug. Positive clinical data from this ongoing trial for refractory RCC, NSCLC, and Melanoma was presented in May 2024.
- What is the latest collaboration for Evogene's subsidiary AgPlenus?
- In February 2024, AgPlenus announced a licensing and collaboration agreement with Bayer to develop a new sustainable weed control solution.
- What is the latest development regarding Lavie Bio's Yalos™ bio-inoculant product?
- In November 2023, Lavie Bio announced the expansion of its bio-inoculant product for spring wheat, Yalos™, to durum and barley. In July 2024, Lavie Bio announced the commercial expansion of Yalos™ to winter wheat.
- What is Evogene's status on the stock exchanges?
- Evogene is public on TASE since June 2007 and public on NASDAQ since November 2013.
Team · 16
Ofer Haviv
President & CEO
Gabi Tarcic
Chief Development Officer
Ilia Zhidkov
Chief Technology Officer
Liat Foigel Wejgman
Vice President of Human Resources
Olga Nissan
Vice President of Business Development
Polina Ravzin
Vice President of Finance
Nir Nimrodi
Chairperson of the Board
Sarit Firon
Independent Director
Leon Y. Recanati
Independent Director
Dan Falk
Independent Director
Adrian Percy
Director
John Irwin
Scientific Advisory Board
Dan Major
Scientific Advisory Board
Dorit Kreiner
Chief Financial Officer
Oded Shoseyov
Independent Director
Ziv Kop
Independent Director
Sectors & technology
Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Business model
B2B
Highlights
1 PatentsVerified
Tags
sustainable-farmingcropsbiotechnologyplant-genomicsagtechbreedingbig-databiofuelclimate-techgenomicschemicalsartificial-intelligencegeneticsseedspharmaceuticals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | evogene.com |
|---|---|
| linkedin.com/company/100603 | |
| facebook.com/evogene123 | |
| Wikipedia | en.wikipedia.org/wiki/Evogene |
| Wikidata | wikidata.org/wiki/Q6981538 |
Identifiers & details
| Legal name | Evogene Ltd. |
|---|---|
| Founded | 2002-1 |
| Employees (exact) | 38 |
| Offices | Rehovot |
| Market cap | $9.3M |
| Status reason | Public on TASE on Jun, 2007;Public on NASDAQ on Nov, 2013; |
| Wikidata QID | Q6981538 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2007-06 | TASE | EVGN | |
| IPO | 2013-11 | NASDAQ | EVGN | $84.8M |
Radar intelligence
Patents
| EPO | 245 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
Web history (Wayback)
| Domain | evogene.com |
|---|
Wikidata
| QID | Q6981538 |
|---|
Certificate / subdomain footprint
| Subdomains | 38 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 512838723 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 1999-10-10 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | לא מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2006 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | גד פינשטיין 13 רחובות |